Dr Aapro talks to ecancertv at EBCC 9 about the different factors that influence the efficacy of endocrine therapy versus chemotherapy in HER2− breast cancer patients.

Aapro says there is a debate to be had with regards to how the best form of treatment is decided. The MAGIC survey showed that factors such as age and tumour size are given most attention whilst HR positive /HER2 negative/BC status is routinely overlooked to the detriment of patient care, he argues.

The survey was made available online for physicians participating in multidisciplinary breast cancer teams with ≥5 years of experience in treating BC and included modules assessing respondent characteristics and their clinical decisions regarding ACT for 896 randomly generated patient profiles.

Issues surrounding the cost and availability of endocrine therapy also contribute to international differences in treatment decisions. He argues that more tools need to be made available to physicians to enable more informed treatment decisions to be made for this patient subset.